Tirzepatide hub
Microdose tirzepatide: definitions, evidence, cost, and providers
Separating approved-tirzepatide evidence from compounded low-dose marketing.
Microdose tirzepatide means using tirzepatide below its labeled maintenance dose. Tirzepatide is a dual GIP and GLP-1 receptor agonist — a different mechanism from semaglutide. Its weight-management evidence comes from the SURMOUNT program, including the SURMOUNT-4 withdrawal trial and the SURMOUNT-MAINTAIN reduced-dose maintenance design. This hub separates that approved-product evidence from compounded low-dose marketing, covers the no-approved-oral distinction, and links to cost, providers, safety, and research. Compounded tirzepatide is not FDA approved.
Approved tirzepatide products
Tirzepatide is the active ingredient in Zepbound and Mounjaro, both injectable. There is no FDA-approved oral tirzepatide of any kind, which makes any compounded 'oral tirzepatide' claim entirely outside approved-product evidence.
Since no oral tirzepatide is approved, a compounded oral or sublingual tirzepatide has no approved counterpart to borrow credibility from; absorption and effect are unestablished.
The trials behind tirzepatide
- SURMOUNT-4: continued tirzepatide vs placebo after a lead-in — regain after withdrawal.
- SURMOUNT-MAINTAIN: a 5 mg reduced maintenance dose vs maximum tolerated dose and placebo.
What the evidence shows
- Tirzepatide's dose-response is established for the approved product in its pivotal program.
- SURMOUNT-MAINTAIN provides specific evidence for a 5 mg reduced maintenance dose, and SURMOUNT-4 shows regain after withdrawal.
What the evidence does not show
- That a compounded sub-therapeutic 'tirzepatide microdose' reproduces those trial results.
- That any oral tirzepatide is approved or evidence-backed — none is.
Ingredient identity & verification
Compounded tirzepatide raises the same ingredient-identity and pharmacy-verification questions as any compounded injectable, without an approved oral form to anchor expectations. See pharmacy verification.
Explore
- Complete tirzepatide microdosing guide
- Cost · providers · evidence review
- Oral & sublingual · injectable
- Maintenance · vs microdose semaglutide
Frequently asked questions
Is microdose tirzepatide FDA approved?
No. There is no FDA-approved 'tirzepatide microdose'. Compounded low-dose tirzepatide is not FDA approved.
Is there an approved oral tirzepatide?
No. No oral tirzepatide is FDA approved in any form; compounded oral tirzepatide claims sit entirely outside approved-product evidence.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.